Mass Tort brief
Mass Tort Brief: UK Class Action Limits & Litigation Funding Scrutiny
Ministers move to restrict opt-out litigation while courts lower costs for motor finance claims and US infant formula trials loom.
Mass Tort
British courts cleared procedural hurdles for mass consumer litigation — making it cheaper for funding firms to sue UK motor finance lenders.
BackgroundUK motor finance lenders face massive liability after regulators and courts found car dealers received undisclosed discretionary commission payments. Thousands of consumers are seeking compensation under Financial Conduct Authority redress frameworks.
- The ruling in Angel v Black Horse allows over 5,000 individual car finance claims to proceed on consolidated legal forms under CPR 7.3.
- Grouping claims cuts filing fees and administrative hurdles, enabling litigation funding firms to scale consumer class actions efficiently.
- The procedural win arrives as the Supreme Court considers whether auto finance brokers owed fiduciary duties over hidden commissions.
Mass Tort
Ministers are moving to restrict UK opt-out class actions — raising legal hurdles to protect British businesses from US-style litigation exposure.
BackgroundThe UK Competition Appeal Tribunal regime allowed opt-out collective proceedings to grow rapidly, pushing total pending claim values past £160 billion. Corporate groups have lobbied ministers to curb speculative litigation funded by private capital.
- Proposals include raising certification standards to screen out weak class actions before expensive disclosure phases begin.
- The government plans to introduce filing fees tied to overall claim values and clarify rules around third-party litigation funding.
- Concurrently, the Law Commission is updating the Consumer Protection Act to modernize liability rules for digital products and AI.
Mass Tort
Reckitt's legal exposure enters a critical phase in US federal court — where a negative bellwether trial could trigger billions in mass tort settlement demands.
BackgroundReckitt subsidiary Mead Johnson and competitor Abbott Laboratories face thousands of US lawsuits alleging they failed to warn parents and hospitals that cow's-milk-based formula increases necrotizing enterocolitis risks in premature infants. Previous state court verdicts resulted in hundreds of millions in damages.
- The trial in federal multidistrict litigation serves as a critical test case to establish settlement benchmarks across thousands of pending claims.
- Plaintiffs allege Mead Johnson marketed specialized premature infant formula while concealing known gastrointestinal risks.
- The legal outcome carries massive financial liability risks for UK-listed Reckitt, directly impacting London investors and company valuation.
Mass Tort
Growing scrutiny over third-party class action funding is driving calls for FCA oversight — threatening to impose strict capital rules on legal financiers.
BackgroundThird-party litigation funders back large-scale class actions in exchange for a share of court damages. Following court rulings restricting certain funding fee structures, legal battle lines have formed over how the industry should be regulated in the UK.
- The report warned courts and defendants operate in a transparency blind spot regarding who finances mass group claims.
- Civitas called for mandatory FCA capital adequacy rules to prevent funding firms from collapsing during multi-year court cases.
- The study recommended strict sanctions screening to ensure offshore or hostile foreign capital does not fund UK court actions.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
